Edgewise Therapeutics Stock Gains After Corporate Update
Edgewise Therapeutics shares rose 3% on January 13 after outlining 2026 priorities, including key drug trial milestones. Analysts maintain positive ratings.
Topic
Latest reporting and analysis tagged with clinical trials.
Edgewise Therapeutics shares rose 3% on January 13 after outlining 2026 priorities, including key drug trial milestones. Analysts maintain positive ratings.
Erasca Inc. shares jumped over 20% to a multi-year high after HC Wainwright raised its price target to $11. The move followed the company's presentation of preliminary clinical data at a healthcare conference.
Arcturus Therapeutics, a biotech firm, is drawing investor interest with its mRNA therapies for cystic fibrosis and OTC deficiency. Wall Street analysts project significant stock growth.